Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.77 |
| ▸ | HPGD | P15428 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | STAT6 | P42226 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinepazide SCHEMBL8839976 | 1.00 | ALDH1A1 (0.77) | ALDH1A1KDM4EHPGDKMT2ATP53 | |
| Cinepazide SCHEMBL11009911 | 0.97 | KDM4E (0.72) | ALDH1A1KDM4EHPGDKMT2ATP53 | |
| Cinepazide SCHEMBL27666991 | 0.96 | KDM4E (0.71) | ALDH1A1KDM4EHPGDKMT2ATP53 | |
| Cinepazide SCHEMBL1062368 | 0.96 | KDM4E (0.71) | ALDH1A1KDM4EHPGDKMT2ATP53 | |
| SCHEMBL28790703 | 0.95 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDKMT2ATP53 | |
| Fumaric Acid SCHEMBL11710489 | 0.95 | KDM4E (0.69) | ALDH1A1KDM4EHPGDKMT2ATP53 | |
| SCHEMBL10646641 | 0.93 | KDM4E (0.67) | ALDH1A1KDM4EHPGDKMT2ATP53 | |
| SCHEMBL10646647 | 0.93 | KDM4E (0.67) | ALDH1A1KDM4EHPGDKMT2ATP53 | |
| Cinepazic Acid SCHEMBL2734241 | 0.87 | ALDH1A1 (0.70) | ALDH1A1KDM4EHPGDKMT2ATP53 | |
| Cinepazic Acid SCHEMBL10795476 | 0.87 | ALDH1A1 (0.70) | ALDH1A1KDM4EHPGDKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1093 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118130678-B | Liquid chromatography-mass spectrometry detection method for 14 drugs of dizziness, syncope and cerebral apoplexy in blood | 中国民用航空局民用航空医学中心 | 2025-06-10 | — | — | CN | claimed |
| CN-119950718-A | Pharmaceutical composition containing STING agonist and application thereof | 杭州星鳌生物科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| US-20250129016-A1 | PHOTOREDOX METHODS FOR RADIOCYANATION OF ARENES AND USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-04-24 | — | — | US | claimed |
| US-20240325362-A1 | NOVEL THERAPEUTIC METHOD FOR ENHANCING MITOCHONDRIAL FUNCTION, TREATING MITOCHONDRIAL DISEASES THEREBY, AND COMPOUNDS USED THEREIN | STANDIGM INC. (KR) | 2024-10-03 | — | — | US | claimed |
| CN-118130678-A | Liquid chromatography-mass spectrometry detection method for 14 drugs of dizziness, syncope and cerebral apoplexy in blood | 中国民用航空局民用航空医学中心 | 2024-06-04 | — | — | CN | claimed |
| CN-112028856-B | Preparation method of cinepazide maleate intermediate | 康普药业股份有限公司 | 2024-03-26 | — | — | CN | claimed |
| WO-2024051847-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING FACIAL NERVE MICRO-ENTRAPMENT SYNDROME AND USE THEREOF | 北京达尔文细胞生物科技有限公司 | 2024-03-14 | — | — | WO | claimed |
| WO-2024051845-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING SEQUELAE STAGE FACIAL NERVE PARALYSIS, AND USE THEREOF | 北京达尔文细胞生物科技有限公司 | 2024-03-14 | — | — | WO | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| CN-115894507-A | Method for synthesizing (+) -canna oensis alkali and application thereof | 昆明医科大学 | 2023-04-04 | — | — | CN | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5830497-A | Medicated plaster containing basic physiologically active agents and/or salts thereof | NITTO DENKO CORPORATION (JP) | 1998-11-03 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| EP-0387751-B1 | Medicated plasters | NITTO DENKO CORP (JP) | 1994-06-08 | — | — | EP | claimed |
| WO-1993008801-A1 | PREVENTION OF DRUG-INDUCED AGRANULOCYTOSIS WITH FREE RADICAL SCAVENGERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-05-13 | — | — | WO | claimed |
| EP-0387751-A2 | Medicated plasters | NITTO DENKO CORPORATION (JP) | 1990-09-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129016-A1 | PHOTOREDOX METHODS FOR RADIOCYANATION OF ARENES AND USE THEREOF | RCC2, PPOX, FTO | ALDH1A1 2660/4885KDM4E 290/4885HPGD 1203/4885 |
| US-20240325362-A1 | NOVEL THERAPEUTIC METHOD FOR ENHANCING MITOCHONDRIAL FUNCTION, TREATING MITOCHONDRIAL DISEASES THEREBY, AND COMPOUNDS USED THEREIN | MCU, NLN, FH | ALDH1A1 3088/4885KDM4E 1832/4885HPGD 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.